To include your compound in the COVID-19 Resource Center, submit it here.

CStone gets Chinese rights to Agios' ivosidenib

CStone Pharmaceuticals Co. Ltd. (Suzhou, China) gained exclusive rights from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) to develop and commercialize ivosidenib (AG-120) in China, including Hong Kong and Macau, and Taiwan

Read the full 291 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE